Skip to main content

stock

CELU · Celularity Inc

Revenue $5.43M last quarter, down 5% on a year earlier; no insider buys or sales filed in 90 days; last 8-K filed Oct 29: other event.

Follow CELU free

Price

Loading the CELU chart…

Chart by TradingView

The business

What the company does and what it reports, from its SEC filings.

What it is

We are a cellular and regenerative medicine company focused on advancing health longevity and redefining the standard of care for age-related disease using novel therapies derived from the post-partum human placenta. The objective of extending health longevity is to meaningfully reduce the duration and severity in which an individual experiences aging-related degenerative diseases and disorders associated with increased mortality towards the end of life. Aging is known to be a major risk factor for many degenerative disorders and diseases across multiple high-value therapeutic areas, including immunology and regenerative medicine. Common to all degenerative disorders and diseases is the progressive loss of function or structure (or both) of affected tissues and organs driven by underlying cellular dysfunction.

From the 10-K for the fiscal year ended Dec 31, 2025, filed Apr 30, 2026.

Read the 10-K on SEC
Sector
Life Sciences (SEC office)
Industry
Pharmaceutical Preparations (SIC 2834)
Employees
115
Headquarters
Florham Park, NJ
Incorporated in
DE
Fiscal year ends
December
Exchange
Nasdaq
Fractional shares
No
Listed options
Yes
Filer category
<br>Emerging growth company
Formerly
GX Acquisition Corp. (until 2021)
Shares outstanding
32,450,679 as of Oct 19, 2026 (XBRL frame )
Filer (SEC EDGAR)
EDGAR filing index

Key stats

Valuation and the ratios that use the live price are free with an account.

Start free to see this

Deep value

NCAV
-$125.25M
NCAV per share
-$3.86
NNWC
-$127.24M
NNWC per share
-$3.92

Expectations

Free cash flow
—
Free cash growth, last 5 years
—
Revenue growth, last 5 years
13.2%

Margins

Gross
—
Operating
-264.3%
Net
-245.7%

Returns

ROE
—
ROA
-47.7%

Health

Current ratio
0.1x
Debt/equity
—

Trailing twelve months to Jun 30, 2026; balance sheet at Jun 30, 2026.

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profitOperating incomeNet incomeFiling
Jun 30, 2026$5.43M—-$4.24M$706,000
10-Q filed Oct 20, 2026
Mar 31, 2026$3.85M—-$10.13M$874,000
10-Q filed Oct 20, 2026
Assembled from more than one filing; the filing above is only the newest of them.
Dec 31, 2025$4.10M—-$22.06M-$24.36M
10-K filed Apr 30, 2026
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Sep 30, 2025$5.28M—-$12.90M-$23.08M
10-Q filed Nov 14, 2025
Jun 30, 2025$5.74M—-$15.86M-$24.52M
10-Q filed Oct 20, 2026
Mar 31, 2025$11.43M—-$10.49M-$19.75M
10-Q filed Oct 20, 2026
Assembled from more than one filing; the filing above is only the newest of them.
Dec 31, 2024$18.13M—-$9.28M-$13.29M
10-K filed Apr 30, 2026
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Sep 30, 2024$9.30M—-$11.53M-$16.10M
10-Q filed Nov 14, 2025
Cash
$586,000
Debt
—
Net cash
—
Current assets
$6.45M
Current liabilities
$59.74M
Working capital
-$53.29M
Total liabilities
$131.70M
Assets
$96.17M
Equity
-$35.53M

Balance as of Jun 30, 2026.

SEC data as of Nov 17, 2026

Earnings moves

No results filings

CELU has filed no 8-K results release since Oct 6, 2025.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
Dec 31, 2025$26.55M-$61.31M-$91.72M—
Dec 31, 2024$54.22M-$38.36M-$57.89M-$6.56M
Dec 31, 2023$22.77M-$192.29M-$196.29M-$39.73M
Dec 31, 2022$17.98M-$25.60M$14.19M-$143.11M
Dec 31, 2021$21.34M-$109.06M-$100.12M-$116.30M
Dec 31, 2020$14.28M-$151.93M-$208.23M-$91.03M
Dec 31, 2019—-$1.68M$5.88M—

What it filed

Material events and 5% ownership filings from the last year.

Company filings

2 offering filings in 12 months

events

  • Other event
    Oct 298-K
  • Executive or director change
    Sep 298-K
  • Material agreementNew debtUnregistered share saleExecutive or director change

    Director succession

    Sep 288-K
  • Other event
    Sep 148-K
  • Executive or director change

    Officer departure, abrupt

    Aug 78-K
  • Listing standard notice
    Jul 298-K

5% owners ()

  • PHILIP & DANIELE BARACH FAMILY TRUST

    Stake update

    29.0%Sep 28SCHEDULE 13D/A
  • PHILIP & DANIELE BARACH FAMILY TRUST

    Stake update

    15.8%Jun 23SCHEDULE 13D/A
  • PHILIP & DANIELE BARACH FAMILY TRUST

    Stake update

    20.1%Apr 22SCHEDULE 13D/A
  • PHILP & DANIELE BARACH FAMILY TRUST

    Activist stake

    9.6%Apr 3SCHEDULE 13D
  • Lincoln Alternative Strategies LLC

    Stake update

    Below 5%Feb 11SCHEDULE 13G/A

Owners and trading

Insider, politician and fund moves, short interest, and the volume traded off the exchange.

Insiders, politicians and funds

Insider trades, last 90 days

No insider buys or sales filed in the last 90 days.

Politician trades, last 90 days

No politician trades filed in the last 90 days.

Funds

None of the tracked funds held this at their last 13F.

Short interest

Hard to borrow: Alpaca will not lend it for shorting

  • Shares short

    534,811

  • Of shares outstanding

    1.6%

  • Days to cover

    2.3

  • Change since last report

    +21.1%

Settlement date Oct 30, 2026

Off-exchange short volume, 20 days

57.6%

Through Nov 17, 2026

Of the volume reported to FINRA's off-exchange facilities, market makers' hedging included. It is not short interest.

Short interest and short volume: FINRA

Off-exchange and dark pools

About 55.2% of shares traded off the exchanges

Period ending Oct 30, 2026, FINRA

Week of Oct 12, 2026, published by FINRA 2 to 4 weeks later

  • Dark pools (ATS)6.7%
  • Wholesalers and other dealers93.3%

Venues, week of Oct 12, 2026

Top dark pools

  1. INCR INTELLIGENT CROSS LLC3,530
  2. CGXS ONECHRONOS1,633
  3. EBXL LEVEL ATS1,516
  4. IATS IBKR ATS945
  5. KCGM VIRTU MATCHIT ATS920

This shows where shares traded, not who bought or sold. Most off-exchange volume is retail orders filled by wholesalers.

Source: FINRA

Members see

  • Signals: which strategies fired on CELU, and the evidence behind each
  • Options positioning: the levels dealers are hedged around
  • Technicals: trend and momentum readings
  • Earnings moves: how the price moved after each report
  • News: stories counted once across outlets
Start free to see these

Comments · 0

No comments yet.

Be the first to say something about CELU.

nakagai

Signals on CELU come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Follow CELU free

Not financial advice. Read the terms that govern posting here.